Vera Therapeutics, Inc.
Clinical trials sponsored by Vera Therapeutics, Inc., explained in plain language.
-
New monthly shot aims to control kidney disease
Disease control OngoingThis study tests a drug called atacicept given once a month to adults with IgA nephropathy, a kidney disease. The goal is to see if it lowers certain proteins linked to the disease and is safe. About 90 people will take part in this Phase 2 trial.
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for kidney disease: drug aims to slow damage in IgA nephropathy
Disease control OngoingThis phase 3 study tests the drug atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the decline in kidney function compared to a placebo. Participants must have …
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC